Full Press Release Details
FRANKLIN LAKES, N.J. , Dec. 7, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today introduced a simplified way for hospitals to manage intravenous (IV) medication to help improve safety and reduce waste.
National data show that 90 percent of hospital patients receive an IV medication during their stay 1 . However, a manual IV compounding process is prone to errors, with an average error rate of 9 percent for chemotherapy, injectables and total parenteral nutrition (TPN) infusions 2 . In addition, 7 percent to 15 percent of oncology budgets are spent on infusions that are prepared, but never get used 3 , resulting in unnecessary waste.
During the 50 th Annual American Society of Health-system Pharmacists (ASHP) Midyear Clinical Meeting being held Dec. 6-10 in New Orleans BD introduced a new, automated IV management solution built on the combined technologies of BD and CareFusion, which BD acquired in March. This is the first solution to include BD and CareFusion technologies working together to create a simplified and safer medication management system.
"Combining BD and CareFusion technologies creates a safer and more simplified way to manage IV medication at hospitals," said Ranjeet Banerjee , worldwide president of Medication Management Solutions for BD. "We will continue to integrate and innovate to develop medication management solutions that help clinicians deliver the safest and most efficient care."
The unique end-to-end IV management process on display at booth #2339 demonstrates a cohesive approach to reducing the opportunities for human error, protecting health care workers from occupational hazards and increasing efficiency to enable nurses and pharmacists to spend more time with patients. For more information please visit: www.bd.com/ashp .
About BD BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com .
1 iData Research, US Market for Vascular Access Devices and Accessories, Peripheral Intravenous Catheter Market, page 23. 2014.
2 Flynn et al. (1997) paper. Flynn EA, Pearson RE, Barker KN. Observational study of accuracy in compounding i.v. admixtures at five hospitals. Am J Health Syst Pharm. 1997;54(8):904-912
3 Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents: The UZ Ghent experience. J Oncol Pharm Practice. 2001; 6: 146-152.
Matt Coppola BD Public Relations 201.847.7370 [email protected]
Monique N. Dolecki BD Investor Relations 201.847.5378 [email protected]
SOURCE BD (Becton, Dickinson and Company)